STAT+: Pharmalittle: More top hospitals aren’t offering Biogen Alzheimer’s drug; Pfizer may lower Covid pill price in poor countries until supplies rise
Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the Pharmalot campus, where the official mascot awaits a play date and the short person is, once again, sleeping in. As for us, we are engaged in the usual routines of readying our to-do list and brewing cups of stimulation. Our choice today, for those tracking such things, is southern pecan, all the way from New Orleans. Feel free to join us. Remember, no prescription is required, so no need to track rebates. Meanwhile, here are some tidbits. Hope you have a smashing day and, as always, do keep in touch. We appreciate your feedback and suggestions. …
The organization that negotiates supply contracts on behalf of more than 95% of the nation’s academic hospitals estimates its members are ordering just one to five vials of the controversial Biogen (BIIB) Alzheimer’s medicine each day, STAT reports. And another 15 university-affiliated hospitals are not offering the drug, including Johns Hopkins, the University of California, Los Angeles, and the University of Michigan. The disinterest in the drug is yet another blow to an already-catastrophic commercial rollout for the medicine, which the company had hoped would be a blockbuster product for the estimated 5.8 million Americans with Alzheimer’s.
Continue to STAT+ to read the full story…
